Natera's Legal Action: Natera has expanded its patent infringement lawsuit against NeoGenomics, including an additional patent related to the RaDaR tests, following a court's approval.
Court Injunctions: The District Court previously issued a preliminary and permanent injunction against NeoGenomics' earlier RaDaR test, and Natera is now seeking full remedies against the current version of the test.
NEO
$11.67+Infinity%1D
Analyst Views on NEO
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.67 USD with a low forecast of 11.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast NEO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEO is 13.67 USD with a low forecast of 11.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.670
Low
11.00
Averages
13.67
High
17.00
Current: 11.670
Low
11.00
Averages
13.67
High
17.00
BofA
Neutral
maintain
$11 -> $13
2025-12-15
New
Reason
BofA
Price Target
$11 -> $13
2025-12-15
New
maintain
Neutral
Reason
BofA raised the firm's price target on NeoGenomics to $13 from $11 and keeps a Neutral rating on the shares. The firm is updating it price targets for Life Sciences & Diagnostic Tools stocks under its coverage, the analyst tells investors. Headwinds are expected to fade, and markets are expected to normalize in 2026, firm adds. The firm believes the biggest upside for the sector will be a return to spending by Biopharma, leading BofA to favor companies with higher exposure to research and development.
Piper Sandler
Overweight
maintain
$11 -> $12
2025-11-10
Reason
Piper Sandler
Price Target
$11 -> $12
2025-11-10
maintain
Overweight
Reason
Piper Sandler raised the firm's price target on NeoGenomics to $12 from $11 following quarterly results. The firm keeps an Overweight rating on the shares.
BofA
Neutral
maintain
$11
2025-10-29
Reason
BofA
Price Target
$11
2025-10-29
maintain
Neutral
Reason
BofA raised the firm's price target on NeoGenomics to $11 from $6.50 and keeps a Neutral rating on the shares after "a solid quarter." The firm views the quarterly update as "constructive," but sees questions on the sustainability of the growth rate and the competitive position, the analyst tells investors.
Leerink
Market Perform
maintain
$12 -> $14
2025-10-28
Reason
Leerink
Price Target
$12 -> $14
2025-10-28
maintain
Market Perform
Reason
Leerink raised the firm's price target on NeoGenomics to $14 from $12 and keeps a Market Perform rating on the shares. The company reported a Q3 beat and is taking investor feedback by proving "beatable guidance and realistic targets," the analyst tells investors in a research note.
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
